GSR Notification #227: Paving the Way to Clinical Research in India (Part I)

GSR Notification #227: Paving the Way to Clinical Research in India (Part I)

The New Drugs and Clinical Trials Rules, 2019 was declared by the ministry of health and family welfare on 25th March 2019 (GSR Notification #227). The key focus of the new set of rules is to encourage advances in clinical research in India. The rules are meant to revolutionize the regulatory aspects for the conduct of clinical trials and the subsequent approval of new drugs. The New Drugs and Clinical Trials Rules, 2019 has been effective from 25th March 2019; however, the chapter four of the rules which pertains to “Ethics committee for biomedical and health research” came into action from 21st September 2019.

The new rules supersede Part XA and Schedule Y of Drugs and Cosmetics Rules and are applicable to all new drugs, investigational new drugs (INDs) for human use, clinical trial, bioequivalence/bioavailability study and ethics committee.

Application fees and modified approval formats

The application fees have been hiked for Phase 1 to 4 clinical trials. Additionally, application and approval formats have been modified. Some of the modified forms are mentioned below:

  • Form CT04 – Clinical Trial Application Form (Replaces Form 44)
  • Form CT 04 A- Automatic Approval Information to CDSCO
  • Form CT 06 - Permission to Conduct CTs by CDSCO
  • Form CT 16- Application to grant of License to Import of New Drug for Clinical Trials (Replaces Form 12)

Definitions have been revised

To bring in more clarity, many definitions have been newly incorporated, while some have been modified. As per the new definition, an orphan drug is defined as drug used to treat condition which affects not more than 5 lac persons in India.

Application review periods and automatic approvals

For the review and approval of clinical trial (CT) applications, fixed timelines have been put down.

  • Ninety working days for global clinical trials
  • Thirty working days for investigational new drugs (INDs) being developed in India. To encourage research and development in India, a new provision of “automatic approvals”

been introduced. If no response is received from the central licencing authority to the applicant within the said period (30 days), the permission to conduct clinical trial shall be deemed to have been granted by the central licencing authority. In such cases, before trial initiation the applicant is required to inform the central licencing authority in Form CT-4A; the central licencing authority on the basis of the said

Ethics committee

The new rules have incorporated significant changes in the constitution of ethics committee (EC). As per the new rules, the ethics committee should have a minimum of seven members from medical, non-medical, scientific and non-scientific areas with.

  • At least, one lay person
  • One woman member
  • One legal expert
  • One independent member from any other related field such as social scientist or representative of non-governmental voluntary agency or philosopher or ethicist or theologian

    At least 50% of members should not be affiliated with the institute or organization in which EC is constituted and every member of the EC shall be required to undergo such training and development programs.

    Two types of ethics committee have been defined:

    • Ethics committee for clinical trial,
    • Ethics committee for Biomedical and health research

Ethics committee registration certificate would be granted in Form CT-02 within a period of 45 working days. The validity of registration has been increased to a period of five years from the date of its issue. Application for the renewal of the registration can be submitted 90 days prior to the date of the expiry of the registration to ensure deemed continuity. As per the new rule, when a clinical trial site does not have its own EC, clinical trial at that site may be initiated after obtaining approval of the protocol from the EC of another trial site; however, in such cases the approving ethics committee should take responsibility for the study at another site or center and the approving ethics committee should be located within the same city or within the radius of 50 kilometres of the clinical trial site.


New Drugs and Clinical Trials Rules, 2019, Ministry of Health & Fam. Welfare, Notification, G.S.R. 227(E), (March 19, 2019).

Related Articles

Drug |
Clinical Trial Process For Drugs In India

Clinical Trial Process For Drugs In India

Medical Devices |
Current Regulatory Scenario for Conducting Medical Device Clinical Trials in India

Medical devices complement the physician’s or surgeon’s expertise in examination, diagnosis, treatment, or follow-up.

Drug |
Biologicals |
GSR Notification #227: Paving the Way to Clinical Research in India (Part I)

The New Drugs and Clinical Trials Rules, 2019 was declared by the ministry of health and family welfare on 25th March 2019 (GSR Notification #227).

Contact Us

Please feel free to talk to us if you have any questions. We endeavour to answer within 24 hours.

Book a consultation

Contact us to book a consultation for your new product launch